AI주식인사이트AI Stock Insight
C

펩트론

087010KOSDAQ

44.5 / 100

Reference Date: 2026-10-23

Financial Score15.0 / 40
News Sentiment12.5 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 31.1% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Peptron develops smart pharmaceuticals using peptide engineering and sustained-release technology, operating a GMP large-scale production facility for clinical trials and commercial products. The pharmaceutical industry is characterized by high R&D costs and long-term profitability, with the sustained-release drug sector maintaining an oligopolistic structure due to high manufacturing barriers even after patent expirations.

Number of Employees

160people

Average Salary

58.1M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
16.57Industry Average 1.200.0Point

13.8x industry avg (risky)

ROE
-9.41Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
21.10Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲36.5% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼16.3% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -22.9% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (5%, downtrend)

Current 100,900Won52-week high 386,00052-week low 84,000
1-month return0.0Point

1m -31.08% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0